---
title: "Body Composition Peptides"
slug: "bodycomp"
type: "category"
url: "https://peptidesciencethailand.com/peptides/bodycomp"
description: "Weight loss peptides Thailand: Semaglutide, Tirzepatide, AOD-9604, Cagrilintide. Fat loss and metabolic research compounds. specialist required."
---
# Body Composition Peptides

Body composition peptides target fat metabolism through growth-hormone-related pathways, offering mechanisms of action fundamentally different from traditional weight loss approaches. The two compounds in this category, Tesamorelin and AOD-9604, both leverage the growth hormone system's fat-metabolizing properties but through distinct approaches: Tesamorelin stimulates the pituitary to produce endogenous GH (with full downstream effects), while AOD-9604 replicates only the C-terminal fragment responsible for lipolysis without affecting IGF-1 or glucose metabolism. This category addresses the growing recognition that body composition, the ratio of lean tissue to adipose tissue, is a more meaningful health metric than body weight alone. Visceral adipose tissue, in particular, is strongly linked to cardiovascular disease, insulin resistance, systemic inflammation, and metabolic syndrome. Both compounds show preferential effects on visceral fat, making them particularly relevant for metabolic health beyond cosmetic body composition goals. Tesamorelin holds FDA approval for HIV-associated lipodystrophy, providing a robust clinical evidence base including Phase III trial data demonstrating 15-18% visceral fat reduction. AOD-9604 has received FDA GRAS status and has Phase IIb clinical trial data. This level of clinical evidence distinguishes body composition peptides from many other research compounds in the peptide space. All protocols require specialist supervision with baseline and ongoing metabolic monitoring to ensure safe, effective outcomes integrated with proper nutrition and exercise programming. The pharmacological distinction between these two compounds is critical for understanding this category. Tesamorelin is a full GHRH analogue that stimulates the anterior pituitary to release growth hormone in pulsatile patterns that mimic physiological secretion. This means Tesamorelin produces a broad spectrum of GH-mediated effects beyond fat metabolism, including improved lipid profiles, potential cognitive benefits through IGF-1, enhanced sleep quality, and tissue maintenance effects. The clinical trade-off is that full GH axis stimulation requires more comprehensive monitoring including IGF-1 levels, glucose metabolism, and thyroid function. AOD-9604 takes a targeted approach by isolating amino acids 176 through 191 of the growth hormone molecule, the specific fragment responsible for lipolytic activity. This isolation means AOD-9604 produces fat metabolism effects without raising IGF-1, affecting blood glucose, or stimulating cell proliferation, resulting in a cleaner safety profile that requires less intensive monitoring. The choice between these approaches depends on whether the patient needs targeted fat metabolism support alone or comprehensive GH axis optimization.

> Body composition peptides modulate growth hormone pathways and fat metabolism, requiring specialist oversight. Baseline body composition analysis, metabolic panel, fasting glucose, and lipid profile are essential before initiating any protocol. These compounds should be integrated with diet and exercise optimization, they are not substitutes for lifestyle modification.

## Compounds in this Category

- [Tesamorelin](/compounds/tesamorelin) — Growth hormone-releasing hormone analogue. Reduces visceral adipose tissue and enhances body composition.
- [AOD-9604](/compounds/aod-9604) — Modified growth hormone fragment. Stimulates lipolysis without affecting blood sugar or growth markers.
- [Ipamorelin](/compounds/ipamorelin) — Highly selective growth hormone secretagogue peptide that stimulates natural GH pulsatility without affecting cortisol or prolactin.
- [MK-677 (Ibutamoren)](/compounds/mk-677) — Orally active ghrelin receptor agonist that stimulates sustained growth hormone release without peptide injection.
- [LGD-4033 (Ligandrol)](/compounds/lgd-4033) — Non-steroidal SARM with high androgen receptor affinity, studied for lean mass accretion and bone mineral density support.
- [GW1516 (Cardarine)](/compounds/gw1516) — Selective PPAR-delta receptor agonist that shifts cellular metabolism toward fatty acid oxidation and enhances endurance.
- [5-Amino-1MQ](/compounds/5-amino-1mq) — Small molecule NNMT inhibitor studied for its effects on cellular energy expenditure, fat metabolism, and metabolic reprogramming.
- [Tesofensine](/compounds/tesofensine) — Small molecule triple monoamine reuptake inhibitor originally studied for neurodegeneration, now researched for appetite regulation and metabolic effects.
- [DHH-B (Dihydrohonokiol-B)](/compounds/dhh-b) — Synthetic derivative of honokiol with selective GABA-A receptor modulation studied for anxiolytic, metabolic, and body composition effects.
- [Semaglutide](/compounds/semaglutide) — GLP-1 receptor agonist. Modulates appetite signaling and glycemic regulation for body composition research.
- [Retatrutide](/compounds/retatrutide) — Triple agonist targeting GIP, GLP-1, and glucagon receptors for advanced metabolic research.
- [Tirzepatide](/compounds/tirzepatide) — Dual GIP/GLP-1 receptor agonist. Twincretin peptide for advanced glycemic and body composition research.
- [Somatropin (HGH)](/compounds/somatropin) — Recombinant human growth hormone. Direct GH supplementation for body composition and metabolic research.
- [CI Blend Pen](/compounds/ci-blend-pen) — Pre-formulated blend of CJC-1295 and Ipamorelin targeting synergistic growth hormone pulse optimization through dual-receptor activation.
- [TCI Blend Pen](/compounds/tci-blend-pen) — Advanced triple-peptide blend combining Tesamorelin, CJC-1295, and Ipamorelin for comprehensive growth hormone axis optimization through multi-receptor engagement.
- [Cagrilintide](/compounds/cagrilintide) — Long-acting amylin receptor agonist for appetite regulation and metabolic optimization in clinical research.

## Comparison Matrix

| Compound | Primary Mechanism | GH Axis Effect | IGF-1 Impact | Blood Glucose Effect | Clinical Evidence Level |
| --- | --- | --- | --- | --- | --- |
| Tesamorelin | GHRH Agonist → Full Pulsatile GH Release | Full pituitary stimulation | Increases IGF-1 | May affect glucose metabolism | FDA-Approved (Phase III trials) |
| AOD-9604 | GH Fragment 176-191 → Isolated Lipolysis | No pituitary stimulation | No IGF-1 change | No effect on glucose | FDA GRAS + Phase IIb trials |
| Ipamorelin | Ghrelin Receptor Agonist (GHS-R1a) | 1-2 weeks | 8-12 weeks | Subcutaneous | GH release/lean mass |
| MK-677 | Non-Peptide GH Secretagogue | 1-2 weeks | 8-16 weeks | Oral | GH/IGF-1 elevation/appetite |
| LGD-4033 | Selective Androgen Receptor Modulator | 1-2 weeks | 8-12 weeks | Oral | Lean mass/strength |
| GW1516 | PPAR-delta Agonist | 1-2 weeks | 8-12 weeks | Oral | Endurance/fat oxidation |
| 5-Amino-1MQ | NNMT Inhibitor | 2-4 weeks | 8-12 weeks | Oral | Fat metabolism/NAD+ preservation |
| Tesofensine | Triple Monoamine Reuptake Inhibitor | 1-2 weeks | 12-24 weeks | Oral | Appetite suppression/weight loss |
| DHH-B | GABA-A Receptor Modulation | 1-2 weeks | 4-8 weeks | Oral | Cortisol reduction/stress management |

## Choosing Between Body Composition Peptide Compounds

The choice between Tesamorelin and AOD-9604 depends on metabolic profile, health goals, risk tolerance, and willingness to engage in comprehensive monitoring. A specialist would evaluate several factors to determine which compound best matches the clinical situation. Tesamorelin is typically preferred when the patient seeks comprehensive metabolic optimization beyond isolated fat loss. Its full GH axis stimulation provides benefits across multiple body systems: improved lipid profiles with reduced triglycerides and improved HDL ratios, potential cognitive enhancement through IGF-1 signaling, improved sleep architecture, and tissue maintenance effects. Patients with documented GH decline confirmed through stimulation testing or low IGF-1 levels are particularly strong candidates for Tesamorelin. However, Tesamorelin requires more intensive monitoring including quarterly IGF-1 levels, fasting glucose, and thyroid panels to ensure metabolic safety. AOD-9604 is typically preferred when isolated fat metabolism support is the primary goal and the patient wants to avoid GH axis stimulation. Its clean safety profile with no effect on IGF-1 or glucose metabolism makes it suitable for patients who have contraindications to full GH stimulation, those with pre-diabetic glucose profiles who cannot tolerate potential glucose effects, and patients who prefer simpler monitoring protocols. AOD-9604 is also preferred in patients for whom the potential proliferative effects of IGF-1 elevation represent an unacceptable risk. Both compounds work optimally when combined with structured nutrition and exercise programming. Administering AOD-9604 during fasted states, typically first thing in the morning before food intake, optimizes its lipolytic effects by aligning compound activity with the body's natural fasted metabolic state. Tesamorelin's evening administration aligns with the natural nocturnal GH pulse, amplifying physiological secretion patterns. A specialist would design administration timing and lifestyle integration recommendations specific to your daily routine and metabolic goals.

## Safety Considerations & Contraindications for Body Composition Peptides

Body composition peptides interact with growth hormone pathways and metabolic systems, creating specific contraindication profiles that must be evaluated before initiating any protocol. The distinction between Tesamorelin's full GH axis stimulation and AOD-9604's isolated lipolytic mechanism means their contraindication profiles differ significantly. Tesamorelin is contraindicated in individuals with active malignancies, particularly those with hormone-sensitive cancers, as its IGF-1 elevation can promote tumor cell proliferation. Patients with pituitary tumors or conditions affecting pituitary function should not use GHRH agonists. Uncontrolled diabetes represents a relative contraindication, as GH can transiently impair insulin sensitivity and worsen glycemic control. Patients with diabetic retinopathy specifically should avoid Tesamorelin due to the theoretical risk of IGF-1 promoting retinal neovascularization. Pregnancy is an absolute contraindication as GH axis modulation could affect fetal development. AOD-9604 has a more favorable contraindication profile due to its isolated mechanism. Because it does not affect IGF-1 or glucose metabolism, many of the contraindications specific to full GH axis stimulation do not apply. However, individuals with known hypersensitivity to growth hormone fragments should avoid the compound. AOD-9604 has emerging research in cartilage regeneration contexts, but individuals with joint conditions should be aware that this application remains investigational. Both compounds require caution in individuals with eating disorders, as combining peptide-mediated fat metabolism with disordered eating behaviors could produce dangerous metabolic states. Patients with a BMI below the healthy range should not use fat metabolism compounds. Individuals taking thyroid medications may need dosage adjustments when using Tesamorelin, as GH can affect thyroid hormone metabolism. Corticosteroid users should be aware that chronic corticosteroid use can suppress the GH axis, potentially limiting Tesamorelin's effectiveness while also complicating metabolic monitoring. specialist monitoring for body composition protocols should include baseline and quarterly body composition analysis via DEXA scan, metabolic panels, fasting glucose, and for Tesamorelin users specifically, IGF-1 levels and thyroid function tests.

## Quality Guide: Body Composition Peptide Quality Standards

Body composition peptides require specific quality considerations related to their growth-hormone-derived structures and the precision required for accurate metabolic dosing. Understanding these quality markers helps ensure the compound being used will produce results consistent with published clinical research. Tesamorelin is a forty-four amino acid peptide, making it one of the more complex compounds to synthesize accurately. Its structure includes a trans-3-hexenoic acid modification at the N-terminus that is essential for its enhanced binding affinity to GHRH receptors and its extended half-life compared to native GHRH. Quality verification must confirm both the peptide sequence accuracy and the presence of this modification through mass spectrometry analysis. Without the modification, the compound would behave like native GHRH with a half-life of only minutes, rendering it clinically impractical at standard dosing intervals. AOD-9604 is a shorter peptide fragment of sixteen amino acids with a disulfide bond between cysteine residues that is essential for maintaining the three-dimensional structure required for biological activity. Quality testing must verify both sequence accuracy and proper disulfide bond formation, as incorrectly folded peptide with mismatched or absent disulfide bonds would have significantly reduced or absent lipolytic activity. The peptide's relatively small size makes synthesis straightforward, but the disulfide bond adds a quality control step that distinguishes properly manufactured product from inferior alternatives. Both compounds require precise concentration measurement for accurate dosing, as the therapeutic window for body composition peptides involves specific microgram quantities that must be reliably delivered. Each vial should contain a verified quantity of lyophilized peptide with documented reconstitution instructions for achieving the target concentration. Overconcentrated or underconcentrated preparations compromise dosing accuracy and clinical outcomes. High-quality body composition peptides undergo comprehensive quality testing including HPLC purity analysis, mass spectrometry identity confirmation, endotoxin testing, and sterility verification. Temperature-controlled logistics should ensure temperature-sensitive compounds maintain stability throughout transit, and certificates of analysis provide batch-specific documentation for a specialist's records.

## Frequently Asked Questions

### How do body composition peptides differ from weight loss drugs?

Body composition peptides target fat metabolism through growth-hormone-related mechanisms rather than appetite suppression, thermogenesis, or nutrient absorption blocking. Tesamorelin stimulates pulsatile GH release for enhanced lipolysis, while AOD-9604 directly activates fat-burning enzymes. These mechanisms preserve lean tissue while reducing fat, improving body composition rather than simply reducing scale weight.

### What medical considerations apply to body composition peptides?

Both Tesamorelin and AOD-9604 are compounds studied in clinical research, typically requiring qualified medical supervision. Growth-hormone-related compounds require baseline metabolic assessment including body composition analysis, fasting glucose, lipid panel, and hormonal markers. Ongoing monitoring ensures metabolic safety and optimizes protocol effectiveness.

### Which body composition peptide should I choose?

Tesamorelin provides broader GH benefits (body composition + cognitive + recovery) but affects IGF-1 and glucose metabolism, requiring more monitoring. AOD-9604 provides isolated fat-metabolic effects without IGF-1 or glucose changes, making it simpler to manage. A specialist would recommend based on metabolic profile, health goals, and any contraindications.

### Do body composition peptides replace diet and exercise?

No. Body composition peptides enhance the body's fat metabolism mechanisms but work best when integrated with proper nutrition and regular exercise. They are not substitutes for lifestyle modification. A specialist would typically recommend concurrent diet and exercise optimization to maximize results and ensure sustainable body composition improvements.

### How long do body composition changes take?

Fat metabolism changes are gradual. Tesamorelin clinical trials measured significant visceral fat reduction over 12-26 weeks. AOD-9604 results typically become measurable after 6-8 weeks with protocols running 12-20 weeks. Medical-grade body composition analysis (DEXA scan) provides more accurate progress tracking than scale weight, which can be misleading if lean tissue is maintained while fat decreases.